Trial Information

Summary: Chronic Lymphocytic Leukemia

A study to determine the safety, tolerability of weekly administration of a study drug in subjects with resistant or relapsed Chronic Lymphocytic Leukemia

Geron Corporation is conducting a research study to determine the safety, tolerability, and maximum tolerated dose of an experimental study drug in subjects with relapsed or resistant Chronic Lymphocytic Leukemia. The study will also determine if the study drug limits disease progression.

To qualify, you must:

• Be at least 18 years old
• Have active Chronic Lymphocytic Leukemia that has relapsed from or resistant to prior treatment regimens
• Have a life expectancy of at least 3 months

You will not qualify if you:

• Do not require a change in your treatment regimen for your disease
• Have an active second cancer or history of another cancer within 2 years
• Are pregnant or lactating
• Have an active autoimmune disorder
• Have significant heart disease
• Have known HIV infection
• Have a psychiatric disorder or altered mental status
• Have a serious infection
• Have uncontrolled bleeding

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:14 AM